Yes Augment, the trial wont affect anything in regards to a sale of the Consumer Healthcare group. An aquisition probably wont have a huge effect either. You see these small pharma product acquisitions occur from these big companies and they hardly hit the share price at all. So often there is no impact on the market cap. All it might do is ease the acquisition path by showing longevity for a core asset or two. Its hard to judge if that would make buying it worthwhile or not.
Pfizer sell down of OTC assets, page-5
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.8¢ |
Change
0.003(1.72%) |
Mkt cap ! $152.5M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.0¢ | 14.5¢ | $24.55K | 167.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 612610 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 400972 | 7 |
View Market Depth
| Last trade - 13.08pm 12/09/2024 (20 minute delay) ? |
| ALA (ASX) Chart |